Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

29452 ARTÍCULOS , VIENDO DEL 2326 AL 2340

Navigating the roads ahead for Alzheimer's disease

Stirrups R.

Lancet Neurol. 2024 Oct;23(10):971. doi: 10.1016/S1474-4422(24)00374-0.

Current pharmacophore based approaches for the development of new anti-Alzheimer's agents

Sharma P, Sharma S, Yadav Y, Shukla P, Sagar R.

Bioorg Med Chem. 2024 Nov 1;113:117926. doi: 10.1016/j.bmc.2024.117926. Epub 2024 Sep 13.

The multiple roles of chronic stress and glucocorticoids in Alzheimer's disease pathogenesis

Burke MR, Sotiropoulos I, Waites CL.

Trends Neurosci. 2024 Nov;47(11):933-948. doi: 10.1016/j.tins.2024.08.015. Epub 2024 Sep 21.

REAL AD-Validation of a realistic screening approach for early Alzheimer's disease

Leuzy A, Heeman F, Bosch I, Lenér F, Dottori M, Quitz K, Moscoso A, Kern S, Zetterberg H, Blennow K, Schöll M.

Alzheimers Dement. 2024 Nov;20(11):8172-8182. doi: 10.1002/alz.14219. Epub 2024 Sep 23.

Effect of long-term pharmacological treatments on Alzheimer disease: A systematic review and network meta-analysis

Deng X, Li D.

Medicine (Baltimore). 2024 Sep 20;103(38):e39753. doi: 10.1097/MD.0000000000039753.

Understanding genetics, sex and signaling: Implications of sex-dependent APOE4-neutrophil-microglia interactions for Alzheimer's and tauopathies

Haag N, Bremer J, Zempel H.

Signal Transduct Target Ther. 2024 Sep 23;9(1):252. doi: 10.1038/s41392-024-01967-1.

Post-Hoc Assessment of Cognitive Efficacy in Alzheimer's Disease Using a Latent Growth Mixture Model in AMBAR, a Phase 2B Randomized Controlled Trial

Ayasse ND, Stewart WF, Lipton RB, Gomez-Ulloa D, Runken MC.

Curr Alzheimer Res. 2024;21(5):353-365. doi: 10.2174/0115672050316936240905064215.

Progress of researches on the mechanism of acupuncture treatment for Alzheimer's disease by modulating synaptic plasticity

Ren DL, Wei YT, Su ML, Zhu TT, Yan XK.

Zhen Ci Yan Jiu. 2024 Aug 25;49(8):858-866. doi: 10.13702/j.1000-0607.20230279.

Microglia and gut microbiota: A double-edged sword in Alzheimer's disease

Bano N, Khan S, Ahamad S, Kanshana JS, Dar NJ, Khan S, Nazir A, Bhat SA.

Ageing Res Rev. 2024 Nov;101:102515. doi: 10.1016/j.arr.2024.102515. Epub 2024 Sep 24.

Phyto-nanotechnology: A novel beneficial strategy for Alzheimer's disease therapy

Ganguly SC, Sangram S, Paul S, Kundu M.

Neurochem Int. 2024 Nov;180:105868. doi: 10.1016/j.neuint.2024.105868. Epub 2024 Sep 25.

Lost in translation: Inconvenient truths on the utility of mouse models in Alzheimer's disease research

Granzotto A, Vissel B, Sensi SL.

Elife. 2024 Sep 27;13:e90633. doi: 10.7554/eLife.90633.

Non-Pharmacological Exercise Randomized Controlled Trials in Alzheimer's Disease

Wang N, Tai HC, Tzeng IS.

J Alzheimers Dis. 2024;101(s1):S537-S544. doi: 10.3233/JAD-240418.

The role and mechanism of dapagliflozin in Alzheimer disease: A review

Chen P, Liang L, Dai Y, Hui S.

Medicine (Baltimore). 2024 Sep 27;103(39):e39687. doi: 10.1097/MD.0000000000039687.

What's in It for Me? Contextualizing the Potential Clinical Impacts of Lecanemab, Donanemab, and Other Anti-β-amyloid Monoclonal Antibodies in Early Alzheimer's Disease

Jin M, Noble JM.

eNeuro. 2024 Sep 27;11(9):ENEURO.0088-24.2024. doi: 10.1523/ENEURO.0088-24.2024. Print 2024 Sep.

NMDARs in Alzheimer's Disease: Between Synaptic and Extrasynaptic Membranes

Escamilla S, Sáez-Valero J, Cuchillo-Ibáñez I.

Int J Mol Sci. 2024 Sep 23;25(18):10220. doi: 10.3390/ijms251810220.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias